Royalty Report: Drugs, Cancer, Therapeutic – Collection: 245950

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Pharmaceuticals
  • Diagnostic
  • cell therapy
  • Antibody
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 245950

License Grant
The Japanese Licensor grants an exclusive license, with the right to grant sublicenses, under the Licensed IP Rights to conduct research and to develop, make, have made, use, offer for sale, sell and import Products in the Territory for use in the Field.
License Property
The Licensor is engaged in research and development of pharmaceutical product called TM-411, known as Tamibarotene.

The patents are regarding manufacturing method and Polymorphism and  combination use.

The Product shall mean any therapeutic or preventative pharmaceutical products containing the Compound as an ingredient.

The Compound shall mean the compound known as TM-411 (Tamibarotene), and any parts, analogs and derivatives thereof.

The trademark shall mean OSALEUKIN.

Field of Use
Field 1 shall mean the pharmaceutical prevention or treatment of acute promyelocytic leukemia (APL).

Field 2 shall mean the pharmaceutical prevention or treatment in human hematological malignancies, including but not limited to Multiple myeloma (MM), Myelodysplastic syndrome (MDS), Chronic myelomonocytic leukemia (CMMoL), Chronic Myelocytic leukemia (CML) and Acute myelocytic leukemia (AML) and solid tumor indications except Hepatocelluar carcinoma (HCC). Field shall collectively mean Field 1 and Field 2.

IPSCIO Record ID: 245951

License Grant
Licensor of Japan grants an exclusive license, with the right to grant sublicenses, under the Licensed IP Rights to conduct research and to develop, make, have made, use, offer for sale, sell and import Products in the Territory for use in the Field 1, and Field 2.
License Property
The technology shall mean the compound known as TM-411, known as Tamibarotene,  and any parts, analogs or derivatives thereof.

The licensed patents refer to manufacturing method for preparing benzoic acid derivatives and Polymorphism.

Product shall mean any therapeutic or preventative pharmaceutical product made from or comprising Technology for human use in the Field.

Field of Use
Field 1 shall mean the pharmaceutical prevention or treatment in humans of the following indications acute promyelocytic leukemia (APL).

Field 2 shall mean the pharmaceutical prevention or treatment in humans of the following indications multiple myeloma (MM), myelodysplatic syndrome (MDS), and all solid tumor indications and Field shall collectively mean Field 1 and Field 2.

IPSCIO Record ID: 3282

License Grant
Pursuant to the License Agreement, the Licensor, an University, granted the Licensee a worldwide exclusive License, for our Licensed field, with, inter alia, the right to subLicense, or assign the License in connection with a sale or transfer, including, until April 2020.
Field of Use
The Licensee is exclusive Licensee to the intellectual property in our Licensed field of multiple myeloma and related diseases as well as to prevention and management of treatment related consequences, including myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML).

Licensee field is diagnostics in Multiple myeloma, or MM, a hematologic, or blood, cancer that develops in the bone marrow and specifically affects the plasma cells of the bone marrow.

The Licensee Licensed field includes applications to malignant and non-malignant human or animal pathologies, including but not limited to determining and/or identifying the presence, predisposition, effect of treatment, mode or type of treatment, type of patient susceptibility to treatment or prevention, progress of treatment, current and predicted clinical outcome, and/or therapeutic or prophylactic treatment and/or regimen. These uses, patent, and technology rights exclude using FISH, which is Licensed to a third party.

IPSCIO Record ID: 360156

License Grant
Swss Licensor provided Licensee with a royalty-bearing license (with the right to grant sublicenses through multiple tiers) to utilize patents and know-how to conduct research and to develop, make, use or offer for sale products developed from certain single chain fragment variable compounds known as DLX105 and DLX2751 owned by the Licensor.
License Property
DLX105 and DLX2751 means antibody therapies of various formats including single chain Fv fragments (scFv), IgG and bispecific antibodies.
Field of Use
Field of use is for the treatment for the treatment of solid and hematological malignancies.

Hematologic malignancies are cancers that affect the blood, bone marrow, and lymph nodes. This classification includes various types of leukemia (acute lymphocytic (ALL), chronic lymphocytic (CLL), acute myeloid (AML), chronic myeloid (CML)), myeloma, and lymphoma (Hodgkin's and non-Hodgkin's (NHL)).

IPSCIO Record ID: 26488

License Grant
The Licensor grants to the Licensee worldwide rights to Azacitidine, Vidaza.
License Property
Vidaza is the subject of a completed and published Phase III study indicating its safety and efficacy in the treatment of myelodysplastic syndromes, or MDS, a bone marrow disorder characterized by the production of abnormally functioning, immature blood cells.  The myelodysplastic syndromes are a diverse collection of hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells and risk of transformation to acute myelogenous leukemia or AML.
Field of Use
The field of use relates to the medical industry.

IPSCIO Record ID: 359061

License Grant
Included with this license and collaboration agreement is a license grant upon voluntary termination.

With respect to the applicable Reversion Compounds being terminated, Licensor grants, effective upon such termination, an exclusive even us to Licensor. sub-licensable, worldwide license under the Licensor Reversion Technology to research, develop, import, use, make. have made, offer for sale and sell Reversion Compounds and Reversion Products including as part of a Licensee Combination Therapy in the Field in the Territory.

License Property
Licensors Reversion Technology means Licensor Technology that both was actually used or generated by Licensor or its Affiliates or Sublicensees with respect to the applicable Reversion Compound or Reversion Product, and is necessary to continue development, manufacture or commercialization without unreasonable delay of the applicable Reversion Compound or Reversion Product.

Reversion Compound means NLG919, any Next Generation Compound or any Subsequent Compound.

NLG919 means Licensee’s proprietary small molecule IDO inhibitor known as of the Execution Date as NLG919, or any enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug thereof.

Next Generation Compound means any Compound other than NLG919 that is invented, by or on behalf of Licensee or its Affiliate, whether solely or jointly, as of the Effective Date or thereafter during the Restriction Period, whether or not pursuant to the Research Plan, that is invented or otherwise the subject of research or preclinical development conducted, by or on behalf of Licensor or its Affiliate or Sublicensee, but excluding the pRED Organization, whether solely or jointly, during the Next Gen Research Term, whether or not pursuant to the Research Plan, the composition of matter, manufacture or use of which is Covered by a Valid Claim of a Licensee Patent or Collaboration Patent; or that is an enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug of a Compound described above.

Field of Use
Field means any use.

Indication means any separately defined. well-categorized class of human disease, syndrome or medical condition for which a separate MAA may be filed with a Regulatory Authority. Each different tumor type or a different hematological malignancy as classified by cell lineage (e.g., acute lymphoblastic leukemia is a different Indication from chronic myclogenous leukemia) shall be a separate Indication; however each different line of therapy for a particular tumor type or hematological malignancy will not he considered a separate Indication.

IPSCIO Record ID: 344510

License Grant
Licensor grants the Swiss Licensee an exclusive, non-transferable right and license under Licensor Know-How and Licensor Patents, with the right to grant sublicenses through multiple tiers of Sublicensees, to research, develop, make, have made, import, export, use, sell, offer for sale, have sold and otherwise commercialize the Licensed Product in the Licensed Field in the Licensed Territory.

Licensor grants an exclusive license. with the right to grant sublicenses through multiple tiers of Sublicensees. to use the Licensor Trademarks on or in connection with the commercialization of the Licensed Product in the Licensed Territory in the Licensed Field.

License Property
Licensor is developing a pharmaceutical product under the trademark Estybon®, also known as rigosertib.

The trademark is ESTYBON.

Rigoscrtib is a novel targeted anti-cancer compound currently in a Phase Ill study for the treatment of a group of rare hematologic malignancies called /.1yelodysp!astic Syndromes (MOS) and in a Phase II/Ill study for pancreatic cancer.

The Compound means the substance that is a sodium salt of (E)-2,4,6-trimethoxystyryl-3 carboxymethylamino-4-methoxybenzyl sulfone, or any Derivative/Improvement thereof.

The Patents include among others
Amino substituted sulfones treating proliferative disorders, and,
Composition and Methods for Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Field of Use
The Initial Indications are MDS Oral, MDS IV and Pancreatic Cancer.

IPSCIO Record ID: 372435

License Grant
Licensor grants an exclusive, non-transferable license, with the right to grant sublicenses, under the Licensor Technology, to Exploit the Compounds and the Products in the Field in the Territory.

Licensor grants a non-exclusive license to use the Licensor Trademarks in connection with the Development and Commercialization of the Products.

License Property
Licensor has discovered and is developing a proprietary program that includes a Compound containing CD3 and CD19 specificities and is coded by Licensor as xx-011, with various potential human therapeutic uses.

Compound means xx-011, its derivatives and variants, including molecules that bind both Product Targets and are specifically claimed in Patents that specifically claim the amino acid sequence of xx-011; and any other DART derived from the DART Platform that binds both Product Targets.

DART means a dual affinity re-targeting molecule consisting of two binding arms, whereby the first arm binds a specificity conferred by an antibody variable region and the second arm binds a specificity conferred by a different antibody variable region.

DART Platform means Licensors proprietary platform for generating DARTs.

Indication means a discrete clinically recognized form of a disease, including DLBCL, chronic lymphocytic leukemia, acute lymphoblastic leukemia, mantle cell lymphoma, and follicular lymphoma.

Licensor Trademarks means the trademark DART, trademarks which incorporate the acronym DART, and related logos.

xx-011 is a humanized CD19 x CD3 bispecific DART protein.

Product means any pharmaceutical product, including all forms, presentations, strengths, doses and formulations, including any method of delivery, containing a Compound alone or in combination with other active pharmaceutical ingredients, other than any active pharmaceutical ingredient that is owned or controlled by Licensor, including any Combination Product.

The patents include
—  Covalent Diabodies And Uses Thereof;
—  Covalent Diabodies And Uses;
—  Deimmunized Serum-Binding Domains And Their Use For Extending Serum Half-Life;
—  CD3-Binding Molecules Capable of Binding to Human and Non-Human CD3; and,
—  Bi-Specific Diabodies That Are Capable Of Binding CD19 And CD3 And Uses Thereof.

Field of Use
The development and commercialization agreement is for MGD011, a product candidate that incorporates our proprietary DART technology to simultaneously target CD19 and CD3 for the potential treatment of B-cell malignancies.
B-cell malignancies include non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL).  These include Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. Prognosis and treatment depend on type and stage of the cancer.

The Field means all uses, including the diagnosis, treatment or prevention of any disease in humans.  This agreement specifically discusses the development of xx-011 for Multiple 8-Cell Malignancies.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.